Top Stories
BMS will help build new Bunsen functions for chemical exploration and synthesis planning, extending a partnership that began in 2020 with a five-target drug discovery deal worth up to $2.7 billion.
Senior insider says there are no discussions, quashing recent talk of a potential $400-billion pharma tie-up.
The biotech dosed the first patient in a Phase II trial evaluating its DPP1 inhibitor for chronic obstructive pulmonary disease (COPD).
The companies will construct a facility in Shijiazhuang, China to manufacture biologics drug substances for global markets.
Combined quarterly sales of HIV prevention drugs Descovy and Yeztugo jumped 101%, as overall revenue increased 10% to $7.8 billion.
Conference News
Analyses of long-term TRUST-I and TRUST-II data will examine consistency of efficacy across key patient subgroupsNEW YORK, Aug. 4, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncolog...
TEL AVIV, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that post-hoc data from its Phase ...
University of Colorado Anschutz-led study shows automated oxygen system increases time in target oxygen range and reduces clinician workload compared with standard careAURORA, Colo., Aug. 3, 2026 /PRN...
– Continued commercial execution drives record total revenues of $1.2 billion (+16% YoY) –– Company raises 2026 revenue guidance –– Prepared to launch Ziihera® in HER2+ 1L GEA immediately following FD...
While AbbVie's oncology strategy gets notably less attention than its flagship immunology portfolio, on its recent earnings call, executives highlighted key ADCs that the pharma is leaning on as it continues to build out its post-Humira pipeline.
